Home > Heart Surgery Blog > Aortic Valve Replacement > Clinical Trial Alert: New Medtronic Evolut Low-Risk TAVR Findings!

Clinical Trial Alert: New Medtronic Evolut Low-Risk TAVR Findings!

Written By: Adam Pick, Patient Advocate, Author and Website Founder
Published: May 29, 2024

Big News!

We recently had a very special opportunity to interview Dr. Michael Reardon, the Co-Principal Investigator of the Medtronic Evolut Low-Risk TAVR Clinical Trial, while at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, California. My chat with Dr. Reardon was specifically about the 4-year clinical trial results for the minimally-invasive Medtronic transcatheter aortic valve replacement (TAVR) procedure in low-risk patients.

To learn new findings and research from the Medtronic Evolut Low-Risk TAVR Clinical Trial, click here to see my interview with Dr. Reardon.

Medtronic Low Risk TAVR Clinical Trial with Dr. Michael Reardon

Many thanks to Dr. Reardon for sharing his clinical experiences and research specific to the Medtronic TAVR procedure with our community.

Written by Adam Pick - Patient & Website Founder

Adam Pick is a heart valve patient and author of The Patient's Guide To Heart Valve Surgery. In 2006, Adam founded HeartValveSurgery.com to educate and empower patients. This award-winning website has helped over 10 million people fight heart valve disease. Adam has been featured by the American Heart Association and Medical News Today.

Follow 450K